ERWINAZE® is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.
This site is intended for US residents only.

Patients Home Hero

Helps you
move forward

when hypersensitivity
holds you back

For you—or your child—remission from acute lymphoblastic leukemia (ALL) is a crucial goal of any treatment plan. ERWINAZE can help keep treatment with asparaginase going strong as part of a multi-agent chemotherapeutic regimen. Even if you have an allergic reaction (called hypersensitivity) to another type of asparaginase.

This website will help you learn about how asparaginase works, why your doctor may recommend ERWINAZE, and what to expect from treatment.

For you—or your child—remission from acute lymphoblastic leukemia (ALL) is a crucial goal of any treatment plan. ERWINAZE can help keep treatment with asparaginase going strong as part of a multi-agent chemotherapeutic regimen. Even if you have an allergic reaction (called hypersensitivity) to another type of asparaginase.

This website will help you learn about how asparaginase works, why your doctor may recommend ERWINAZE, and what to expect from treatment.



How
ERWINAZE
can help?



It is a different form of asparaginase that helps your doctor be able to continue needed treatment for acute lymphoblastic leukemia.



How does
asparaginase
work?



Researchers believe that asparaginase works by starving leukemia cells of asparagine, resulting in leukemia cell death.


Results after
ERWINAZE

After switching to ERWINAZE, 78% of patients in a clinical study completed their prescribed course of asparaginase treatment

Results after
ERWINAZE

After switching to ERWINAZE, 78% of patients in a clinical study completed their prescribed course of asparaginase treatment.



ERWINAZE® (asparaginase Erwinia chrysanthemi) is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.